Celldex Therapeutics (CLDX) Cash & Equivalents (2010 - 2026)

Celldex Therapeutics' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $35.7 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 108.5% year-over-year to $35.7 million; the TTM figure through Mar 2026 stood at $35.7 million (up 108.5% YoY), while the FY2025 annual figure was $28.9 million, up 1.82% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $35.7 million, up from $28.9 million in the prior quarter.
• The five-year high for Cash & Equivalents was $115.1 million in Q1 2024, with the low at $17.1 million in Q1 2025.
• The 5-year median for Cash & Equivalents is $28.9 million (2025), against an average of $35.5 million.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents soared 113.98% in 2023, then plunged 85.11% in 2025.
• Celldex Therapeutics' Cash & Equivalents stood at $29.4 million in 2022, then gained by 18.3% to $34.8 million in 2023, then slipped by 18.55% to $28.4 million in 2024, then climbed by 1.82% to $28.9 million in 2025, then rose by 23.75% to $35.7 million in 2026.
• Business Quant data shows CLDX's Cash & Equivalents at $35.7 million in Q1 2026, $28.9 million in Q4 2025, and $36.0 million in Q3 2025.